C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637)
12/2004
12/02/2004	WO2004104032A2 Methods and compositions related to high-titer pseudotyped retroviruses
12/02/2004	WO2003064665A3 Viral vector
12/02/2004	US20040241825 Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages
12/02/2004	US20040241821 Replication competent yellow fever virus for propagation of immunoglobulin conjugate for use in detection tumor associated antigen expression and treatment of cell proliferative disorders in mammals; cancer diagnosis; immunotherapy
12/02/2004	US20040241642 Polynucleotide fragments of an infections human endogenous retrovirus
12/02/2004	US20040241188 Isolated rHMPV comprising partial or complete, genome or antigenome having one or more attenuating nucleotide modifications, anda major nucleocapsid protein, a nucleocapsid phosphoprotein; improved qualities relevant to immunogenicity, safety, protective efficacy and breadth of vaccine coverage
12/02/2004	US20040241187 An inactivated, disrupted influenza virus preparation of a hemagglutinin antigen stabilised by alpha-tocopherol succinate in the absence of thiomersal or at low levels of thiomersal; hemagglutinin detectable by a single radial immunoassay (SRID); mercury-free preservative; administering by any route
12/02/2004	US20040241182 lymphocytes; immunogens; fusion proteins; for treatment/prevention of infection
12/02/2004	US20040241181 Preferentially inducing a more potent CD8+ T cell response to an immunogen by delivering a recombinant simian adenovirus comprising a nucleic acid molecule encoding an immunogen under the control of gene expression regulatory sequences directing expression of the immunogen; HIV; rabies; papilloma virus
12/02/2004	US20040241140 Expression vectors able to elicit improved immune response and methods of using same
12/02/2004	US20040241139 viral genes in covalent junction with foreign, genetically engineered genes; ribonucleic acid segments having upstream splicing donors and downstream splicing acceptor signal surrounding the proximal coding regions; vaccines
12/02/2004	CA2526403A1 New enterovirus, vaccines, medicaments and diagnostic kits
12/02/2004	CA2525698A1 A nucleic acid construct containing a nucleic acid derived from the genome of hepatitis c virus (hcv) of genotype 2a, and a cell having such nucleic acid construct introduced therein
12/02/2004	CA2525603A1 Methods and compositions for the production of adenoviral vectors
12/01/2004	EP1482031A1 Serum-free mammalian cell culture medium, and uses thereof
12/01/2004	EP1481067A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
12/01/2004	EP1480671A2 Recombinant rsv virus expression systems and vaccines
12/01/2004	EP1480665A2 Peptides for recognition and targeting of glial cell tumors
12/01/2004	EP1212428B1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
12/01/2004	CN1551913A Infectious bovine viral diarrhea virus clone and production method and use
12/01/2004	CN1551782A Chimeric flavivirus vectors
12/01/2004	CN1177927C Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgruop B
11/2004
11/30/2004	US6825396 Methods for tissue specific synthesis of protein in eggs of transgenic hens
11/30/2004	US6825036 Genetically engineered cells for use as tool in the generation of vaccines
11/30/2004	US6825027 Method of production of purified hepatitis a virus particles and vaccine preparation
11/30/2004	US6824784 Cold-adapted equine influenza viruses
11/25/2004	WO2004101801A2 Improved method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding generic tools, as well as the applications of these non-pathogenic amplicons vectors
11/25/2004	WO2004101777A1 A recombinant virus comprising an intact tumor-therapeutic antibody with human costant regions and the use thereof
11/25/2004	WO2004101765A2 Methods and apparatus for adeno associated virus purification
11/25/2004	WO2004101621A1 A SPECIFIC IMMUNOGLOBULIN (Ig) Y AGAINST SEVERVE ACUTE RTESPIRATORY SYNDROME (SARS) AND A PREPARING METHOD THEREOF AND COMBINATION PREPARATIOS CONTAINING IT
11/25/2004	WO2004100640A2 Marek’s disease virus vaccine
11/25/2004	WO2004081178A3 Methods and composition for producing infectious hpv stocks
11/25/2004	WO2004022722A3 Lentiviral vectors, related reagents, and methods of use thereof
11/25/2004	WO2004008938A3 A novel method to identify targets for antibiotic development
11/25/2004	WO2003092594A8 Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
11/25/2004	US20040237129 Transgenic rodent model for use in identifying modulators for treatment of cell proliferative disorders; antitumor agents; immunotherapy
11/25/2004	US20040236093 Using chimeric dendritic cells comprising viral epitopes to generate vaccines to prevent and treat viral diseases
11/25/2004	US20040235174 Adenoviral expression vector comprising red fluorescent protein reporter for use as heterologous gene transfer tool
11/25/2004	US20040235173 Production of host cells containing multiple integrating vectors by serial transduction
11/25/2004	US20040235135 Preparing viral nucleotide sequences where immune response-inducing antigen sequences are repositioned in the position closest to the 3' end and viral replication limiting factor gene is repositioned away from 3' promoter; for use in generating vaccine to treat and prevent viral infectious diseases
11/25/2004	US20040235134 Newcastle disease virus infectious clones, vaccines and new diagnostic assays
11/25/2004	US20040235133 Large scale production of packaged alphavirus replicons
11/25/2004	US20040235132 Helper cell comprising coronavirus permissive cell, replicon RNA and helper RNA: for use in producing assembled coronavirus particles which comprise heterologous RNA sequences, is able to infect cells and is unable to complete viral replication in absence of helper RNA; heterologous gene expression
11/25/2004	US20040234953 Viral nucleotide sequences coding envelope proteins for use in preparing antibodies for prevention and treatment of autoimmune disorders
11/25/2004	US20040234950 Method for virus propagation
11/25/2004	US20040234947 Cells for detection of influenza and parainfluenza viruses
11/25/2004	US20040234554 Hepatitis B virus crosslinked with immunogens, epitopes; capsid peptide binding to core protein; vaccine
11/25/2004	US20040234553 Cold-adapted equine influenza viruses
11/25/2004	US20040234552 Avian-paramyxovirus nucleotide sequence; attenuation live vaccine
11/25/2004	US20040234549 Novel recombinant and mutant adenoviruses
11/25/2004	US20040234506 Recombinant RSV virus expression systems and vaccines
11/24/2004	EP1479774A1 Viruses dependent on inducing agents for viral entry into a host cell
11/24/2004	EP1479761A1 New enterovirus, vaccines, medicaments and diagnostic kits
11/24/2004	EP1478759A1 Retroviral vectors pseudotyped with influenza virus hemagglutinin for gene delivery
11/24/2004	EP1478664A1 Tissue specific expression
11/24/2004	EP1478657A2 Sequence analysis of the tetravalent rotavirus vaccine
11/24/2004	EP1078105B1 Replication defective hiv vaccine
11/24/2004	EP0811077B1 A rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
11/24/2004	EP0717752B1 Therapeutic compounds
11/24/2004	CN1548532A Recombinant adenovirus vaccine containing latent membrane protein-2 gene of EB virus
11/24/2004	CN1177042C Recombinant adenovirus of coexpression human P53 gene and human cytokine gene and its preparation method and application
11/23/2004	US6821777 Cell line preparing and producing ovine adenovirus vectors
11/23/2004	US6821511 Transducing cell; incubate cells with nucleotide sequences, insert cells into mammals, monitor mammals for phenotypic adjustment
11/23/2004	CA2012482C Hepatitis c diagnostics and vaccines
11/18/2004	WO2004098530A2 Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
11/18/2004	WO2004098492A2 Trans-golgi network-associated processes, methods and compositions related thereto
11/18/2004	WO2004078778A3 PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
11/18/2004	WO2004075836A9 STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
11/18/2004	WO2003076591A8 Compositions and methods for generating an immune response
11/18/2004	US20040229832 Vaccines containing ribavirin and methods of use thereof
11/18/2004	US20040229792 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
11/18/2004	US20040229362 Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors
11/18/2004	US20040229361 Mammalian cell line for use as tool in preparation of gene transfer sequences; tissue engineering; bioreactor for production of therapeutic proteins
11/18/2004	US20040229336 Using lipo-viro-particles isolated from serum of infected patient to culture, propagate and replicate hepatitis C or hepatitis G virus in culture; genetic vaccines and preventing viral diseases
11/18/2004	US20040229335 Methods and compositions for the production of adenoviral vectors
11/18/2004	US20040228878 Recombinant infectious laryngotracheitis virus and uses thereof
11/18/2004	US20040228876 Composition and Method for Treating Cancer Using Herpes Virus
11/18/2004	US20040228840 Vector for integration of heterologous sequences into poxviral genomes
11/18/2004	US20040228798 A conjugated drug contains virus-like particle is joined to the antigen by a biotin molecule; bioassay; inhibiting HIV infection, viral infection
11/18/2004	CA2524799A1 Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
11/17/2004	EP1477497A1 Humanized immunoglobulins and their production and use
11/17/2004	EP1477494A1 Subunit respiratory syncytial virus vaccine preparation
11/17/2004	EP1476581A2 Recombinant bovine immunodeficiency virus based gene transfer system
11/17/2004	EP1476580A2 Multiple virus replicon culture systems
11/17/2004	EP1476543A1 Viral variants with altered susceptibility to nucleoside analogs and uses thereof
11/17/2004	EP1254229B1 Vector constructs for gene-therapy mediated radionuclide therapy of undifferentiated and medullary thyroid carcinomas and non-thyroidal tumours and the metastases thereof
11/17/2004	EP1252322B1 Herpes virus strains for gene therapy
11/17/2004	EP0942928B1 Subunit respiratory syncytial virus vaccine preparation
11/17/2004	CN1547587A Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof
11/17/2004	CN1546662A Recombinant caspase-6 gene having target activity and its uses in treating tumor
11/17/2004	CN1546658A Artificially recombinant H9N2 hypotype influenza virus and its uses
11/17/2004	CN1546657A Virus lysis method
11/17/2004	CN1546521A Transfer factor specific for SARS virus and method for preparing same
11/17/2004	CN1176210C Novel type coronavirus
11/16/2004	US6818748 Cloning, expression, sequencing, and functional enhancement of monoclonal ScFv antibody against Venezuelan equine encephalitis virus (VEE)
11/16/2004	US6818425 RNA ligase of bacteriophage RM 378
11/11/2004	WO2004096993A2 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
11/11/2004	WO2004096842A2 Sars virus nucleotide and amino acid sequences and uses thereof
11/11/2004	WO2004058801A3 Modified vaccinia ankara expressing p53 in cancer immunotherapy
11/11/2004	US20040224411 Transgenic cell comprising adenoviral vector for use as gene delivery tool; tissue engineering heterologous gene expression; DNA vaccines

1 ... 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 ... 267